Immune Therapeutics Overview
Immune Therapeutics (IMUN) has a ROE of -17.61%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow-17.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Immune Therapeutics (IMUN) currently reports a ROE of -17.61%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Immune Therapeutics's ROE history and peer comparisons.
Immune Therapeutics's ROE of -17.61% is higher than the Healthcare sector average of -75.59%. That is roughly 76.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Immune Therapeutics's current -17.61% should be judged against Healthcare norms (sector average: -75.59%) and against IMUN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -17.61%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Immune Therapeutics, and consider following IMUN for alerts when major investors trade the stock.
Immune Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -17.61% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMUN with unrelated industries.
